1. Home
  2. AIRI vs CTXR Comparison

AIRI vs CTXR Comparison

Compare AIRI & CTXR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Air Industries Group

AIRI

Air Industries Group

HOLD

Current Price

$3.36

Market Cap

15.8M

Sector

Industrials

ML Signal

HOLD

Logo Citius Pharmaceuticals Inc.

CTXR

Citius Pharmaceuticals Inc.

HOLD

Current Price

$0.85

Market Cap

16.6M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
AIRI
CTXR
Founded
1979
2007
Country
United States
United States
Employees
N/A
N/A
Industry
Military/Government/Technical
Biotechnology: Pharmaceutical Preparations
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
15.8M
16.6M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
AIRI
CTXR
Price
$3.36
$0.85
Analyst Decision
Buy
Analyst Count
0
2
Target Price
N/A
$6.00
AVG Volume (30 Days)
287.5K
1.3M
Earning Date
11-14-2025
02-13-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$50,031,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$3.53
$147.57
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$2.77
$0.63
52 Week High
$4.48
$3.40

Technical Indicators

Market Signals
Indicator
AIRI
CTXR
Relative Strength Index (RSI) 56.98 40.03
Support Level $3.20 $0.74
Resistance Level $3.41 $0.85
Average True Range (ATR) 0.14 0.06
MACD 0.00 0.01
Stochastic Oscillator 79.41 33.03

Price Performance

Historical Comparison
AIRI
CTXR

About AIRI Air Industries Group

Air Industries Group is an aerospace and defense company. Its manufactures and designs structural parts and assemblies that focus on flight safety, including landing gear, arresting gear, engine mounts, flight controls, throttle quadrants, jet engines, and other components. The company also provides sheet metal fabrication of aerostructures, tube bending, and welding services.

About CTXR Citius Pharmaceuticals Inc.

Citius Pharmaceuticals Inc is a biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products, with a focus on oncology, anti-infectives in adjunct cancer care and distinct prescription products. It aims to provide therapeutic products that address unmet medical needs yet have a lower development risk than is usually associated with new chemical entities. The company's flagship product candidate is LYMPHIR, an engineered IL-2 diphtheria toxin fusion protein. It operates through a single operating and reportable segment which is focused on developing and commercializing pioneering targeted oncology therapies.

Share on Social Networks: